Fibrosing mediastinitis (FM), also known as sclerosing mediastinitis or mediastinal fibrosis, is rare but fatal. Progressive exudation and proliferation of fibrinous inflammation in the mediastinum replace normal mediastinal fat, potentially encapsulating and compressing the mediastinal and hilar structures [1, 2]. The median age of FM patients in the United States is 42 years [3], but the mean age is 69.5 years according to a small sample of studies in China [4]. The current general view is that FM is a severe fibrotic change caused by an immune response of the mediastinum to various antigens (e.g., Histoplasma capsulatum, or Mycobacterium tuberculosis) [2]. The immune response leads to mediastinal granulomatous lymphadenitis. The host organism triggers an antigen-antibody response that can lead to mediastinal lymphadenitis [5]. The inflammatory lymph nodes may breakdown, resulting in possible spillage of antigens into the mediastinum. This causes mediastinal allergic reactions and inflammatory changes, and long-term repeated chronic inflammatory stimulation leads to the proliferation of abnormal fibrotic tissue. The large amount of proliferating fibrous tissue may compress the mediastinal structures and cause corresponding pathological changes and clinical manifestations. This process may lead to compression of mediastinal structures and obstructive symptoms. The diagnosis of FM requires the exclusion of other possible diseases of the mediastinum. Patients with FM present with varying degrees of pulmonary vascular narrowing or occlusion and involvement of the accompanying airways. The most common symptoms include cough, chest tightness, shortness of breath, bilateral lower extremity edema, pleural effusion, and clinical features of superior vena cava syndrome when the superior vena cava is compressed. Stenosis and even occlusion of the pulmonary artery (PA) and pulmonary vein (PV) are complications caused by FM [1, 6, 7]. There are relatively few treatment options for FM. Interventional therapy is currently a preferred treatment option. However, it is difficult to treat total PV occlusion, and there is a potentially high risk of procedural-related complications. Here, we report a patient with FM-induced PV occlusion who underwent successful endovascular angioplasty using a venous retrograde approach.

A 75-year-old male patient presented with intermittent chest tightness and shortness of breath for more than 1 year. He had a history of paroxysmal atrial fibrillation/flutter, hypertension and tuberculosis. He had no history of smoking or coronary heart disease. Physical examination revealed that the breath sounds decreased in the basal field of the right lung, and the apex was displaced laterally. Laboratory tests revealed an albumin concentration of 35.73 g/l, no abnormalities in liver or renal function, no abnormalities in tumor markers, and an NT-proBNP concentration of 197.80 pg/ml. The pleural effusion was considered leakage. Moreover, no tumor cells were found by pathological examination. Therefore, pleural effusion due to right heart failure or liver, kidney or tuberculosis was excluded. Subsequently, chest X-ray revealed a widened mediastinum. Echocardiography revealed a high probability of pulmonary hypertension (PH), right heart enlargement (right atrial area, 20.1 cm2; right ventricular area, 23.2 cm2), and moderate tricuspid regurgitation (TRV was 3.7 m/s). The left atrial and ventricular sizes were not abnormal, with normal ranges of systolic and diastolic function and a left ventricular ejection fraction of 63%. The right heart catheter (RHC) suggested elevated mean pulmonary artery pressure (mPAP, 35 mmHg), pulmonary artery wedge pressure (PAWP, 11 mmHg) and pulmonary vessel resistance (PVR, 3.6 Wood units). Enhanced chest computed tomography (CT) with contrast showed multiple enlarged lymph nodes and soft tissue densities around both pulmonary hilum in the mediastinum, multiple stenoses and occlusions of bilateral PAs and PVs (stenosis of the left superior PV (LSPV) and occlusion of the right superior PV (RSPV)), and a large amount of pleural effusion on the right side (Fig. 1). Contrast-enhanced CT showed no significant coronary artery stenosis, and the patient had no symptoms of angina. Accordingly, the patient’s pleural effusion was a result of obstruction of venous return due to PV stenosis/occlusion caused by FM, and leakage of fluid was produced by increased hydrostatic pressure in the pleural capillaries. FM-induced PA/PV stenosis and PH were diagnosed.

A, Chest X-ray image showing the drainage tube in the right lung (red arrow). B, Enhanced chest CT: The coronal view shows LSPV stenosis (yellow arrow) and RSPV occlusion (blue arrow). C, Enhanced chest CT: Axial view showing RSPV occlusion (red arrow) and pleural effusion (blue arrow). D, Virtual reconstructed CT image showing LSPV stenosis (yellow arrow) and RSPV occlusion (blue arrow, V1; red arrow, V2)

After consulting with multiple disciplinary teams, including cardiac and thoracic surgeons and pulmonologists, endovascular treatment for pulmonary vein stenosis/occlusion was performed. After successfully puncturing the interatrial septum, an 8.5 F vascular sheath (St. Jude Medical, Inc., MN, USA) was advanced to the left atrium, and a JR4.0 guiding catheter (Johnson, NJ, USA) was advanced to the RSPV. Selective angiography revealed total occlusion of the first and second tributaries of the RSPV (RSPV-V1, 2) (Fig. 2A; Supplementary Video A) with pulmonary vein flow grading (PvFG) grade 0. First, the venous antegrade guidewire approach (defined as the guidewire advancing from the proximal to the distal pulmonary vein) failed to pass through the RSPV-V1 occlusion segment. Subsequently, a Pilot 50 guidewire (Abbott, Chicago, USA) with a microcatheter (FinecrossMG, Terumo Medical, Tokyo, JPN) was passed through the occluded segment of RSPV-V2a and reached its distal end. Serial angioplasty with 1 × 10 mm (Stazuna, Terumo Medical), 1.5 × 15 mm (Springter, Boston Scientific), 2 × 20 mm (Springter, Boston Scientific) and 3 × 30 mm balloons (Sterling™, Boston Scientific) was performed after the true lumen was confirmed by microcatheter angiography (Fig. 2B and C; Supplementary Video A). Angiography revealed severe stenosis in the proximal segment of the RSPV-V2a, the strut of the RSPV-V2b, well-developed collaterals to the occluded RSPV-V2b and a clear-visible distal area of the occluded RSPV-V2b (Fig. 2D and E; Supplementary Video A). After attempting and failing to pass through the occluded segment of RSPV-V2b via the venous antegrade approach (Fig. 2F; Supplementary Video A), we advanced the guidewire to the distal area of V2b through the collateral vessel and passed it through the occluded segment back to the guiding catheter (venous retrograde guidewire approach, defined as the advancement of the guidewire from the distal to the proximal PV) (Fig. 2G; Supplementary Video A). Then, we tried the venous antegrade wire approach again and successfully advanced a Pilot 50 guidewire through the occluded segment to the distal end guided by a retrograde wire (Fig. 2G; Supplementary Video A). After serial ballooning, angiography revealed severe stenosis of the proximal segment of V2b, and a 3-mm diameter stent (3 mm×20 mm, Express™ Vascular SD, Boston Scientific) was implanted (Fig. 2H and M, Supplementary Video A). Additionally, stent implantation was performed in the proximal segment of V2a (Fig. 2N and O; Supplementary Video A). Selective angiography again demonstrated well-expanded stents and no gradient pressures across stents by catheter (Fig. 2L, M and O; Supplementary Video A). No procedure-related complications occurred, and repeat chest CT 12h after stenting showed no lung injury. The symptoms of shortness of breath slightly improved, and the amount of pleural effusion drainage decreased after stenting.

A, Selective angiography showing total occlusion of RSPV-V1 (red arrow), total occlusion of RSPV-V2a (white arrow), and RSPV-V2b (blue arrow). B, A guidewire with a microcatheter (white arrows) was passed through the occluded segment of the RSPV-V2a and reached its distal end. Angiography via a microcatheter showing the distal V2a (white arrows). C, Ballooning (white arrow) of RSPV-V2a. D, Selected angiography showing severe stenosis at the proximal segment of RSPV-V2a (white arrow) and occluded RSPV-V2b (blue arrows). E, A well-developed collateral vessel (red arrows) connected the distal occluded RSPV-V2b (yellow arrows) to the distal RSPV-V2a (blue arrows). F, Failed attempt to pass through the occluded segment of RSPV-V2b (red arrow, guidewire). Blue arrows, the guidewire in V2a. G, The guidewire was advanced to the distal area of V2b through the collateral artery (red arrows) and passed through the occluded segment back to the guiding catheter (white arrows). The venous antegrade wire approach was used again, and a Pilot 50 guidewire (yellow arrows) was successfully advanced through the occluded segment to the distal V2a guided by a retrograde wire. H, Ballooning (yellow arrows) for V2b. I, Selective angiography showed severe stenosis at the proximal V2b (yellow arrows). J, Another projection view showing proximal V2b stenosis (yellow arrows). K, Stenting for V2b (yellow arrows). L, Selective angiography again after stent implantation showing a well-expanded stent (yellow arrows). M, Another projection view showing the well-expanded stent (red arrows). N, Stenting (red arrows) for V2a. O, Selected angiography showing a well-expanded stent in V2a. White arrow, strut of the occluded RSPV-V1

The patient had scheduled follow-ups via phone due to the COVID-19 pandemic, and his symptoms improved compared to those at discharge. The amount of pleural effusion drainage further decreased at the three-month follow-up after stenting. The symptoms improved significantly at the six-month follow-up after the intervention, and the pleural effusion resolved. However, the patient died due to COVID-19-related pneumonia eight months after stenting.